Resources

In part 2 of this Exclusive Interview, Todd Hobbs talks with Diabetes in Control Publisher Steve Freed about the standings of the oral GLP-1 drug and their work on another oral drug.

In part 3 of this Exclusive Interview, Todd Hobbs talks with Diabetes in Control Publisher Steve Freed about the results of the SUSTAIN-7 trial and their implications for diabetes patients.

In part 4 of this Exclusive Interview, Todd Hobbs talks with Diabetes in Control Publisher Steve Freed about the benefits of both an SGLT-2 and GLP-1 injectable, as found in the Dual 9 study.

In part 5 of this Exclusive Interview, Todd Hobbs talks with Diabetes in Control Publisher Steve Freed about the overall results of the Confirm real-world study.

In part 6, the conclusion of this Exclusive Interview, Todd Hobbs talks with Diabetes in Control Publisher Steve Freed about the upcoming focus on treating obesity as well as an oral form of semaglutide.

High cost associated with underuse in certain patient populations, particularly those with lower incomes.

How does the newest insulin delivery method compare to an established system?

Study targets breakfast habits of parents and its effects on their children.

Trial assesses if link exists between severe hypoglycemia and adverse cardiovascular outcomes in veterans.

Low levels thought to contribute to pathogenesis of painful diabetic peripheral neuropathy due to action on dorsal root ganglia.